Cargando…

Molecular Docking and Dynamic Simulation of AZD3293 and Solanezumab Effects Against BACE1 to Treat Alzheimer's Disease

The design of novel inhibitors to target BACE1 with reduced cytotoxicity effects is a promising approach to treat Alzheimer's disease (AD). Multiple clinical drugs and antibodies such as AZD3293 and Solanezumab are being tested to investigate their therapeutical potential against AD. The curren...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hassan, Mubashir, Shahzadi, Saba, Seo, Sung Y., Alashwal, Hany, Zaki, Nazar, Moustafa, Ahmed A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5992503/ https://www.ncbi.nlm.nih.gov/pubmed/29910719 http://dx.doi.org/10.3389/fncom.2018.00034

Ejemplares similares

AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics
por: Eketjäll, Susanna, et al.
Publicado: (2016)

Computational modeling and biomarker studies of pharmacological treatment of Alzheimer's disease
por: Hassan, Mubashir, et al.
Publicado: (2018)

Clinical Bioavailability of the Novel BACE1 Inhibitor Lanabecestat (AZD3293): Assessment of Tablet Formulations Versus an Oral Solution and the Impact of Gastric pH on Pharmacokinetics
por: Ye, Naidong, et al.
Publicado: (2018)

Applying Big Data Methods to Understanding Human Behavior and Health
por: Moustafa, Ahmed A., et al.
Publicado: (2018)

Mechanistic insights into TNFR1/MADD death domains in Alzheimer’s disease through conformational molecular dynamic analysis
por: Hassan, Mubashir, et al.
Publicado: (2021)

Quantile regression to characterize solanezumab effects in Alzheimer's disease trials
por: Chen, Yun-Fei, et al.
Publicado: (2016)

Central pharmacodynamic activity of solanezumab in mild Alzheimer's disease dementia
por: Willis, Brian A., et al.
Publicado: (2018)

Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer's disease
por: Carlson, Christopher, et al.
Publicado: (2016)

Exploration of Potential Ewing Sarcoma Drugs from FDA-Approved Pharmaceuticals through Computational Drug Repositioning, Pharmacogenomics, Molecular Docking, and MD Simulation Studies
por: Hassan, Mubashir, et al.
Publicado: (2022)

Association of hypertension, diabetes, stroke, cancer, kidney disease, and high-cholesterol with COVID-19 disease severity and fatality: A systematic review
por: Zaki, Nazar, et al.
Publicado: (2020)

Delayed-start analysis for demonstrating disease modification of solanezumab
por: Wolters, Frank J., et al.
Publicado: (2015)

Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years
por: Liu-Seifert, Hong, et al.
Publicado: (2015)

Prediction of Site Directed miRNAs as Key Players of Transcriptional Regulators Against Influenza C Virus Infection Through Computational Approaches
por: Hassan, Mubashir, et al.
Publicado: (2022)

Concatenation of molecular docking and molecular simulation of BACE-1, γ-secretase targeted ligands: in pursuit of Alzheimer’s treatment
por: Jabir, Nasimudeen R., et al.
Publicado: (2021)

3293 Region Specific Dysregulation of Dopaminergic Signaling in Mice Displaying Excessive Over-Grooming
por: Foster, Daniel, et al.
Publicado: (2019)

The Application of Unsupervised Clustering Methods to Alzheimer’s Disease
por: Alashwal, Hany, et al.
Publicado: (2019)

Computational prognostic evaluation of Alzheimer’s drugs from FDA-approved database through structural conformational dynamics and drug repositioning approaches
por: Hassan, Mubashir, et al.
Publicado: (2023)

The participation rate of migrant women in gestational diabetes screening in Austria: a retrospective analysis of 3293 births
por: Weiss, Christoph, et al.
Publicado: (2018)

An Alzheimer’s disease category progression sub-grouping analysis using manifold learning on ADNI
por: van der Haar, Dustin, et al.
Publicado: (2023)

Application of predictive models in boosting power of Alzheimer's disease clinical trials: A post hoc analysis of phase 3 solanezumab trials
por: Ezzati, Ali, et al.
Publicado: (2022)

Tyrosinase Inhibitors Naturally Present in Plants and Synthetic Modifications of These Natural Products as Anti-Melanogenic Agents: A Review
por: Hassan, Mubashir, et al.
Publicado: (2023)

A Synaptic Pruning-Based Spiking Neural Network for Hand-Written Digits Classification
por: Faghihi, Faramarz, et al.
Publicado: (2022)

Amyloid‐Related Imaging Abnormalities in the DIAN‐TU‐001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease
por: Joseph‐Mathurin, Nelly, et al.
Publicado: (2022)

Anti-amyloid-β Monoclonal Antibodies as Promising Disease-Modifying Therapies in Alzheimer’s Disease: A Focus on Aducanumab, Lecanemab, Crenezumab, Gantenerumab and Solanezumab
por: Melo, V. S. D., et al.
Publicado: (2023)

Therapeutic Implications of microRNAs in Depressive Disorders: A Review
por: Hassan, Mubashir, et al.
Publicado: (2022)

Role of BACE1 in Alzheimer’s synaptic function
por: Das, Brati, et al.
Publicado: (2017)

Evaluation of dose‐dependent treatment effects after mid‐trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's disease
por: Wang, Guoqiao, et al.
Publicado: (2022)

Nature’s Own Pharmacy: Mushroom-Based Chemical Scaffolds and Their Therapeutic Implications
por: Hassan, Mubashir, et al.
Publicado: (2023)

Kinetics and Molecular Docking Studies of 6-Formyl Umbelliferone Isolated from Angelica decursiva as an Inhibitor of Cholinesterase and BACE1
por: Ali, Md Yousof, et al.
Publicado: (2017)

The Alzheimer's disease β-secretase enzyme, BACE1
por: Cole, Sarah L, et al.
Publicado: (2007)

Highlights in BACE1 Inhibitors for Alzheimer's Disease Treatment
por: Coimbra, Judite R. M., et al.
Publicado: (2018)

Post-Translational Modifications of BACE1 in Alzheimer's Disease
por: Wen, Wen, et al.
Publicado: (2022)

Repurposing food molecules as a potential BACE1 inhibitor for Alzheimer’s disease
por: Mukerjee, Nobendu, et al.
Publicado: (2022)

Molecular docking of fisetin with AD associated AChE, ABAD and BACE1 proteins
por: Dash, Raju, et al.
Publicado: (2014)

Biological Evaluation and Docking Analysis of Potent BACE1 Inhibitors from Boesenbergia rotunda
por: Youn, Kumju, et al.
Publicado: (2019)

BACE1, the Alzheimer's beta-secretase enzyme, in health and disease
por: Vassar, Robert
Publicado: (2012)

BACE1, the Alzheimer’s beta-secretase enzyme, in health and disease
por: Vassar, Robert
Publicado: (2013)

BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease
por: Vassar, Robert
Publicado: (2014)

BACE1 inhibition as a therapeutic strategy for Alzheimer's disease
por: Vassar, Robert
Publicado: (2016)

BACE-1 and γ-Secretase as Therapeutic Targets for Alzheimer’s Disease
por: Maia, Miguel A., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_172ofqv875t2urgghmifqed5k1